ALK mutation and overall survival (OS) in pan-cancer immune checkpoint blockade (IMAGE)
Caption
(A) The Kaplan–Meier survival analysis stratified by ALK mutation status in 1406 cancer patients with 6 tumor types treated with immune checkpoint inhibitors in the discovery cohort. (B) The association between ALK mutation and OS in 1524 patients with 9 tumor types in the validation cohort. (C) Comparison of OS between patients with ALK mutation and patients with ALK non-mutation in 2930 subjects with 11 types of tumors treated with immune checkpoint inhibitors. (D, E) Univariate (D) and multivariate (E) Cox analysis of the association between ALK mutation and OS. ALK, anaplastic lymphoma kinase; CI, confidence interval; CTLA-4, cytotoxic T-lymphocyte-associated antigen 4; HR, hazard ratio; OS, overall survival; PD-1, programmed cell death protein 1; PD-L1, programmed cell death ligand 1; TMB, tumor mutation burden
Credit
Zhiyang Huang, Jiajun Chen, Yan Huang, Hong Zhao, Bin Zhao
Usage Restrictions
Credit must be given to the creator. Only noncommercial uses of the work are permitted. No derivatives or adaptations of the work are permitted.
License
CC BY-NC-ND